Regulatory status record
Cipla Pune warehouse licence cancelled over Reactin Plus (2026)
Last checked 8 October 2026
Maharashtra's FDA cancelled the sale and distribution licences of Cipla Pharma and Life Sciences' Wadki, Pune warehouse on 1 Oct 2026, citing misbranded Reactin Plus tablets, an incomplete recall and storage and record lapses; Cipla's medicines are not banned and the company says it is weighing its options.
- Classification
- Licence suspended
- Decided by
- Food and Drug Administration, Maharashtra (Assistant Commissioner, Drugs, Pune Division 3)
- Reference
- FDA Pune cancellation order of 1 Oct 2026, issued after Bombay High Court directions in Writ Petition 11376 of 2026
- Latest action
- 1 October 2026
- Last checked
- 8 October 2026
Photo: pharmacy-jars by unknown (CC0). All photo credits.
Maharashtra FDA cancels drug sale licence of Pune Cipla facility; 'disappointing decision', says firm
Our team has checked this record against the published reports, last on 8 October 2026. The government order itself is not published online, or we have not found it yet, so we link the best public report. If you have the order, send it to us and we will link it instead.
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Below: Blacklisted's explanationWe explain what has been reported. The report above is the best source we hold.
Key facts
- Company
- Cipla Pharma and Life Sciences Ltd (warehouse at Wadki, Pune)
- Product cited
- Reactin Plus tablets, a Schedule H drug whose pack claimed 'analgesic and antipyretic' use, held to be misbranded
- Other grounds
- Incomplete compliance with a recall; storage and stock-record deficiencies
- Process
- Revised show-cause notice 4 Sep, reply 11 Sep, hearing 21 Sep, order 1 Oct 2026
- Company's response
- Called the decision disappointing and said it is evaluating options
On 1 Oct 2026 Maharashtra's Food and Drug Administration cancelled the drug sale and distribution licences of a carrying-and-forwarding warehouse at Wadki, Pune, run by Cipla Pharma and Life Sciences. The order cites the misbranding of Reactin Plus tablets, a Schedule H medicine whose pack described it as an analgesic and antipyretic, incomplete compliance with a recall, and deficiencies in storage and stock records.
It is the second cancellation. The FDA's first order, of 27 Aug 2026, was withdrawn after the Bombay High Court described it as high-handed. The authority then issued a revised show-cause notice on 4 Sep, received Cipla's reply on 11 Sep and held a hearing on 21 Sep before passing the fresh order. Cipla called the decision disappointing and said it was evaluating its options.
The action concerns one warehouse's licences. It is not a ban on any Cipla medicine.
What this means for you
One warehouse, not the medicines
The order concerns the licence of one distribution warehouse. It does not ban Reactin Plus or any other Cipla product.
This is a record of official orders, not medical advice. Do not stop a prescribed medicine without asking your doctor or pharmacist.
Common questions
Is Reactin Plus banned?
No. The FDA held its pack claims to be misbranding and cancelled the licences of the warehouse that held it. The product itself has not been banned.
Official sources and primary records
- Maharashtra FDA cancels drug sale licence of Pune Cipla facility; 'disappointing decision', says firmNewsOutlook Business · 3 October 2026
- Maharashtra FDA action on Cipla warehouseNewsUNI · 2 October 2026
- Bombay High Court pulls up FDA for high-handed cancellation of Cipla drug licencesNewsBar & Bench · 29 August 2026